Triple-negative breast cancer trials recruiting in North Carolina

All Triple-negative breast cancer trials nationally

Cities in North Carolina

Recruiting trials in North Carolina

• A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
  NCT06999187 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Huntersville
• Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
  NCT07340541 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Chapel Hill
• Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients
  NCT04677816 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Winston-Salem
• MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
  NCT05076760 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Durham
• Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
  NCT04468061 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Chapel Hill
• Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
  NCT06393374 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Charlotte, Fayetteville
• Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells
  NCT06347068 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Chapel Hill
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
  NCT05633654 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Chapel Hill, Charlotte, Durham, Greensboro
• Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
  NCT06084481 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Durham
• Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
  NCT05005403 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Durham, Huntersville
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
  NCT04585750 · Phase: Phase 1, Phase 2 · Ages: 12 Years and older · Sex: All (male and female) · North Carolina: Durham
• Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
  NCT05846789 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Durham